Thursday, November 12, 2026

Goldman Sachs Warns Big Tech ROE to Drop 7 Points as Global AI Spending Races Ahead of Revenue

Goldman Sachs projected a 7 percentage point average decline in return on equity across the five largest US tech companies over the next 12 months, as AI infrastructure spending outpaces revenue generation by 18 to 24 months. Microsoft, Alphabet, Meta, Amazon, and Apple — whose combined market weight shapes global index returns worldwide — face a structural margin drag before AI monetization begins to offset costs. The warning arrives as international institutional investors from sovereign wealt

LM Salvado
LM Salvado

June 17, 2026

Goldman Sachs Warns Big Tech ROE to Drop 7 Points as Global AI Spending Races Ahead of Revenue
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Goldman Sachs forecast a 7 percentage point average decline in Big Tech return on equity over the next year, warning that AI infrastructure spending is outpacing revenue generation globally.1

The June 12 report targets Microsoft, Alphabet, Meta, Amazon, and Apple — the five largest AI infrastructure investors and the dominant weights in indices tracked by pension funds, sovereign wealth funds, and retail investors across Europe, Asia, and the Americas.1

AI hardware and infrastructure investment cycles typically lag revenue generation by 18 to 24 months.1 That structural gap compresses margins before monetization begins. The scale of current spending — larger than any prior technology buildout — extends that drag.

Return on equity measures how efficiently a company converts shareholder equity into profit. A 7-point compression across five of the most profitable businesses in global equity markets would represent a material deterioration in capital efficiency — one that current valuations may not yet reflect.

The S&P 500 returned 9% year-to-date on earnings growth.1 International investors who have rotated into US tech equities on that momentum face direct exposure if Goldman's forecast holds.

The counterargument is timing. AI proponents argue that inference services, enterprise APIs, and cloud AI tools will monetize faster than cloud computing did in the 2010s — a cycle that took most of the decade to turn margin-accretive. China's competing AI infrastructure push adds pressure: US firms cannot slow capex without ceding ground internationally.

Confirming the Goldman thesis requires tracking quarterly ROE across all five companies over four consecutive quarters. A verified average decline of 5 to 9 percentage points would validate the projection.1

The implications extend far beyond Wall Street. ROE compression at this scale ripples through global index returns, analyst estimates in London, Tokyo, and Frankfurt, and the capital allocation decisions of institutions managing trillions in assets internationally. With AI infrastructure spending showing no sign of slowing, the revenue side of that equation is the critical variable for global markets over the next 12 months.

In this story · Knowledge Files

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com